Adipotide vs Tesofensine
A side-by-side research comparison of Adipotide and Tesofensine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Adipotide | Tesofensine |
|---|---|---|
| Full name | Adipotide (FTPP / Prohibitin-Targeting Peptide) | Tesofensine (Triple Monoamine Reuptake Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | Research compound (preclinical) | Phase 3 Clinical Trial |
| Mechanism | A fusion of a prohibitin-targeting peptide and a pro-apoptotic sequence. It binds prohibitin on the vasculature that feeds white fat, inducing apoptosis of those blood vessels, which starves fat cells and causes them to be resorbed. | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. |
| Molecular weight | ~2.6 kDa | 329.4 Da |
| Half-life | Short (hours) | 8-10 days |
| Bioavailability | Subcutaneous injection | High (oral ~93%) |
| Typical dose | Not established for human use | 0.25-0.5 mg |
| Frequency | Research protocols only | Once daily |
| Route | Subcutaneous injection | Oral |
Adipotide reported benefits
- Rapid targeted white-fat reduction (animal models)
- Weight loss without appetite suppression
- Reversal of metabolic markers in obese primates
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Related comparisons
Research and educational reference only. Not medical advice.